Meanwhile, the third-generation TKI osimertinib has shown superiority over erlotinib and gefitinib in terms of PFS, OS, and quality of life, and is preferred for first-line therapy of advanced EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.